Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation

Area of Science:

• Cardiology
• Pharmacology
• Evidence-Based Medicine

Background:

• Comprehensive evidence appraisal for rivaroxaban's benefits and harms in stroke prevention is lacking.
• Nonvalvular atrial fibrillation (NVAF) necessitates effective anticoagulation strategies.

Purpose of the Study:

• To compare the effectiveness and safety of rivaroxaban against other anticoagulants in adults with NVAF.
• To synthesize current evidence on rivaroxaban's comparative profile.

Main Methods:

• Rapid review incorporating randomized controlled trials (RCTs), meta-analyses, and observational studies.
• Evidence appraisal utilized the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
• Searches conducted across multiple databases up to October 2018.

Main Results:

• Rivaroxaban demonstrated noninferiority to warfarin in preventing stroke and systemic embolism.
• Rivaroxaban reduced risks of hemorrhagic stroke, fatal bleeding, and cardiac arrest but increased major gastrointestinal bleeding.
• Observational studies indicated rivaroxaban's potential for lower ischemic stroke, myocardial infarction, and intracranial hemorrhage risk, yet with higher gastrointestinal bleeding and variable mortality risks compared to warfarin.
• Network meta-analyses suggested higher bleeding risks for rivaroxaban compared to apixaban, dabigatran, and edoxaban.

Conclusions:

• Further research is essential to evaluate the long-term comparative effectiveness and safety of rivaroxaban against other novel oral anticoagulants.
• Long-term studies should also investigate the impact on quality of life.